CombinatoRx has signed an all-stock merger agreement with Neuromed.
Clarient Files Registration Agreement With SEC
Clarient has filed a registration statement with the Securities and Exchange Commission on Form S-3 relating to shares of Clarient owned by Safeguard.
Promising Genetic Biomarker Identified for Colorectal Cancer
A new genetic discovery could lead to easier detection of colorectal cancer.
VIVUS’ Qnexa Shows Promise For Diabetics
VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.
Electro-Optical Submits MelaFind for Premarket Approval
Electro-Optical Sciences anounced that it has submitted a Premarket Approval Application to the U.S. Food and Drug Administration for MelaFind.
Biogen Idec, Electro-Optical Among “5 Stocks Approaching Greatness”
Investment website The Motley Fool has published a list of five stocks approaching greatness–and four of them are within the life sciences industry.
Clarient Stock Deal Frees Up Cash for Safeguard Scientifics
Safeguard Scientifics Inc. has received $19.5 million in cash, and freed up another $12.3 million in cash due to one of its portfolio companies completing the second part of a private placement of convertible preferred stock.
TargetScan Touch Proven Effective in Duke Study
A study published in Technology in Cancer Research and Treatment shows that Envisioneering Medical’s TargetScan Touch system is more effective in detecting prostate cancer than traditional biopsy methods.
